top of page

About

​

 

AlloCyte Pharmaceuticals AG is a Swiss biotech company developing oral allosteric integrin modulators to protect organs from tissue-destructive autoimmune diseases. The company's next milestone is clinical proof-of-concept in a high-priority autoimmune disease.  

​​

 

The Need

​

Autoimmune diseases affect 5–8% of the global population, and their prevalence is rising. Despite major advances in immune modulation, there is no oral therapy to effectively and selectively stop the immune system from destroying healthy tissue. AlloCyte was founded to change this.

​

​

The Game Change

​

AlloCyte is developing oral allosteric integrin modulators to resolve a profound immune receptor imbalance associated with disease activity and tissue-destruction in severe autoimmunity. Our fully owned, patent-protected platform used orally demonstrated proof-of-principle in terms of efficacy, tolerability and safety, associated with excellent oral-use pharmacokinetics across preclinical studies. Translational bridging studies in biomaterials of patients suffering from active autoimmune disease confirmed the intended effect profile, supporting advancement toward clinical proof-of-concept. Further, the recent (2026) discovery of previously unknown human genetic states of complete and selective deficiency of AlloCyte's first target integrin deepens the immune-mechanistic understanding of its roles at molecular and cellular levels, introducing the intriguing perspective of biomarker-monitored individualized immune-regulatory precision intervention.

 

​

Team of Competency

​

​Founded by leaders in immunology drug development, AlloCyte combines deep scientific, drug developmental and clinical expertise with strong academic and industry partnerships. Supported by public, private, and corporate funding, the company is advancing its oral lead program toward clinical proof-of-concept.

​

bottom of page